Board Type
Posts Today
Posts Last 30 Days


Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).

Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.

One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.

At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.

THCVHS for the treatment of glaucoma

Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.

According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.

Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.


In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.

Additionally, it has been demonstrated:

  • Skye’s THCVHS formulation enables it to better enter various compartments of the eye vs natural THC
    Its formulation lowers IOP better than leading current prescribed drugs in animal models
    THCVHS or its metabolite (THC) is not detectable in the plasma or brain tissue after topical administration to the eye
    THC in an ex vivo model demonstrated lowering of IOP and the reduction of biomarkers related to fibrosis, inflammation, and vasodilation, supporting a multimodal mechanism of action.

CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical modelsPreliminary data suggest potential analgesic, anti-inflammatory, anti-fibrotic, anti-infective and anti-seizure activity of CBDVHS opening the door to multiple therapeutic applications. We are actively conducting additional preclinical studies to help determine and prioritize a well we defined development plan for CBDVHS.



Our Mission

We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.

Our Vision

Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.

Our Values

Science First
The foundation of Skye Bioscience.

Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.

Commercial differentiated applications to provide therapeutic benefits.

Impact driven
Change makers. Platform solutions that can extend beyond a single disease.


Punt Dhillon


Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

+Read More

Tu Diep,MSc

Senior Vice President, Development 

Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.

+Read More

Richard Janney 

Principal Accounting Officer 

Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.

+Read More

Tom Kim,Esq

General Counsel & Director of IP 

Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.

+Read More

Karam Takhar 

Vice President, Corporate Development & Investor Relations

Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.

+Read More

Board of Directors

Punit Dhillon


Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

+Read More

Jim Heppell,LLB


Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.

+Read More

Margaret Dalesandro,PhD


Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development. 

+Read More

Scientific Advisory Board 

Eduardo Muñoz,MD, PhD

Scientific Advisor

Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.

+Read More

Giovanni Appendino,PhD

Scientific Advisor 

Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation .. 

+Read More

Clinical Advisory Board 

Jeffrey Goldberg,MD, PhD

Ophthalmology Clinical Advisor 

Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.

+Read More

Louis Pasquale,MD, FARVO

Ophthalmology Clinical Advisor 

Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.

+Read More

Robert Ritch,MD

Ophthalmology Clinical Advisor 

Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.

+Read More
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
Skye Bioscience Stockholders Vote in Favor of Arrangement lolroflmao 10/02/2022 03:19:01 AM
NEWS: Skye Bioscience Completes Drug Production for Phase lolroflmao 09/20/2022 10:05:57 AM
NEWS: Skye Bioscience Files Definitive Proxy Statement and lolroflmao 09/01/2022 09:32:42 AM
NEWS OUT: Emerald Health Therapeutics Receives Court Approval lolroflmao 08/26/2022 09:49:28 AM
These guys are full of it. Shareholders speak Scout72 08/12/2022 03:03:00 PM
News: Emerald Health Therapeutics, Inc. Provides Update on lolroflmao 08/12/2022 12:20:34 PM
Cant say I blame the shareholders. EMHTF is Scout72 08/04/2022 02:56:09 PM
#6254 bobbleheadtwin 08/04/2022 07:58:43 AM
BRIEF-Shareholders Oppose Plan Of Arrangement Between Emerald Health bobbleheadtwin 08/04/2022 07:37:35 AM
Skye Bioscience Updates Phase 1 Timeline. lolroflmao 07/20/2022 09:31:39 AM
Wow! Talk about at the buzzer. frozenspokes 06/30/2022 08:48:21 PM
Long-awaited HREC approval FINALLY lands. Phase 1 justs0medude 06/30/2022 08:32:38 AM
#6249 Sk justs0medude 06/07/2022 11:25:22 AM
#6248 bobbleheadtwin 06/06/2022 08:08:11 AM
Our CEO Punit Dhillon will be presenting at RoadShowPartner 05/19/2022 03:17:26 PM
Emerald already owes 25% of Skye, bobbleheadtwin 05/12/2022 10:49:32 AM
NEWS bobbleheadtwin 05/05/2022 09:50:26 AM
NEWS OUT... Skye Bioscience hires CMAX to run lolroflmao 04/28/2022 08:53:39 AM
Skye just filed a 10-K with 83 sections justs0medude 03/28/2022 10:39:34 AM
#6242 frozenspokes 03/03/2022 08:39:48 AM
Skye Bioscience Reports Positive Results for SBI-100 in lolroflmao 02/16/2022 09:52:36 AM
Who else is adding right now? I've justs0medude 02/08/2022 09:51:03 AM
Long hold for the gold Gemgemini19 02/04/2022 04:45:28 PM
That's what most of the long holders think. Dutchpaul1 01/11/2022 12:11:58 PM
this guy said they were going in the mmjbuyer 01/10/2022 02:03:05 PM
so quiet here Dutchpaul1 01/04/2022 11:43:36 AM
Skye Bioscience (SKYE) - RoadShowPartner 12/15/2021 01:59:29 PM
We should start moving in december...finaly Dutchpaul1 11/30/2021 04:09:31 AM
Yikes.... frozenspokes 11/23/2021 05:01:44 PM
Is it just me or is chart looking bobbleheadtwin 11/01/2021 11:27:25 AM
no i did not.. i sold at 0.07 Chefboy69 10/25/2021 09:00:16 PM
You sold and took a loss on the Romes14 10/25/2021 12:31:16 PM
sold and took a loss here. Chefboy69 10/25/2021 09:58:02 AM
Skye recently updated its clinical development strategy and mmjbuyer 10/21/2021 06:13:36 PM
Skye Bioscience Sponsored Research Presented at American Association lolroflmao 10/21/2021 10:42:34 AM
Yep when Company starts issuing shares to fund N.C.LUCKY(7) 10/18/2021 01:56:48 PM
they just created another 80M shares w warrants mmjbuyer 10/14/2021 10:59:26 AM
Over a million on the ask?? Scout72 10/14/2021 09:37:56 AM
Punit way to driver shareholder value. This will mmjbuyer 10/12/2021 08:58:25 PM
This what happens when you have press release Scout72 10/12/2021 02:39:47 PM
#6220 Published 39 mins ago N.C.LUCKY(7) 09/24/2021 01:51:30 PM
#6219 CNBC FAST MONEY pot stock are big winners N.C.LUCKY(7) 09/24/2021 01:30:01 AM
#6218 Awesome News Here.. The U.S. House of Representatives N.C.LUCKY(7) 09/22/2021 12:53:54 AM
#6217 BOOM bobbleheadtwin 09/21/2021 09:16:43 AM
#6216 $SKYE Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts bobbleheadtwin 09/21/2021 09:16:20 AM
#6215 NEWS bobbleheadtwin 09/21/2021 09:08:51 AM
#6214 News 9-14-2021 Change in Director of Principal officer... N.C.LUCKY(7) 09/17/2021 04:21:04 PM
#6213 N.C.LUCKY(7) 09/17/2021 04:21:03 PM
#6212 Time to Buy Pot Stocks! N.C.LUCKY(7) 09/04/2021 03:22:28 AM
#6211 Positive News for SKYE: N.C.LUCKY(7) 08/10/2021 10:34:38 AM
Post Subject